Accenture

R&D

Now is the time for pharma to help solve bias in clinical tr...

Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials.

R&D

Traditional approaches to growth in biopharma are no longer ...

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions.

Patients

To help solve patient distrust in pharma, industry collabora...

The past two years have shone a spotlight on the UK life sciences industry.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

Market Access

A roadmap for adopting New Science

The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways an

Sales & Marketing

Pharma’s post-COVID prospects: the pharmaphorum podcast

In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season.